CANCER RESEARCH

Scope & Guideline

Elevating the standards of cancer research and innovation.

Introduction

Delve into the academic richness of CANCER RESEARCH with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN0008-5472
PublisherAMER ASSOC CANCER RESEARCH
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1941 to 2024
AbbreviationCANCER RES / Cancer Res.
Frequency24 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404

Aims and Scopes

CANCER RESEARCH is dedicated to advancing our understanding of cancer through innovative research and clinical studies. The journal encompasses a wide range of topics related to cancer biology, treatment, and prevention, contributing to the global effort to combat cancer.
  1. Cancer Biology and Mechanisms:
    Research exploring the molecular and cellular mechanisms underlying cancer initiation, progression, and metastasis, including studies on genetic mutations, epigenetic alterations, and the tumor microenvironment.
  2. Therapeutic Strategies and Drug Development:
    Investigations into novel therapeutic approaches, including targeted therapies, immunotherapies, and combination treatments, aimed at improving clinical outcomes for cancer patients.
  3. Biomarkers and Prognostic Indicators:
    Studies focused on identifying and validating biomarkers that can predict cancer progression, treatment response, and patient prognosis, aiding in personalized medicine.
  4. Clinical Trials and Translational Research:
    Reports on clinical trials evaluating new treatments, surgical techniques, and interventions, bridging the gap between laboratory research and patient care.
  5. Cancer Epidemiology and Risk Factors:
    Research analyzing epidemiological data to identify risk factors associated with various cancer types, contributing to prevention strategies and public health initiatives.
  6. Innovative Methodologies:
    Development and application of cutting-edge techniques, such as machine learning, genomic sequencing, and advanced imaging, to enhance cancer research and diagnostics.
CANCER RESEARCH is at the forefront of addressing emerging themes in cancer research, reflecting the latest advancements in technology, treatment, and understanding of cancer biology.
  1. Immunotherapy and Immune Microenvironment:
    A significant increase in studies focusing on immunotherapy, including checkpoint inhibitors and CAR T-cell therapy, as researchers explore the immune landscape's role in cancer progression and treatment response.
  2. Targeted Therapy and Precision Medicine:
    Emerging research on targeted therapies that exploit specific genetic alterations within tumors, alongside studies on biomarkers for patient stratification and personalized treatment plans.
  3. Role of Non-Coding RNAs:
    A growing body of literature investigating the functions of long non-coding RNAs (lncRNAs) and microRNAs in cancer biology, particularly their roles in regulating gene expression, cancer stemness, and treatment resistance.
  4. Metabolic Reprogramming in Cancer:
    Research focusing on the metabolic adaptations of cancer cells, including the study of pathways like glycolysis and ferroptosis, as potential targets for therapeutic intervention.
  5. Multi-Omics Approaches:
    An increase in studies utilizing multi-omics strategies (genomics, transcriptomics, proteomics) to gain comprehensive insights into cancer biology and identify novel therapeutic targets.

Declining or Waning

While CANCER RESEARCH continues to cover a broad spectrum of cancer-related topics, certain themes have seen a decline in prominence over recent years, reflecting shifts in research focus and clinical priorities.
  1. Traditional Chemotherapy Studies:
    Research centered on conventional chemotherapy regimens has decreased as newer targeted therapies and immunotherapies gain traction, leading to a shift in focus toward more personalized and effective treatment modalities.
  2. Basic Research on Non-Malignant Conditions:
    Investigations into benign tumors and non-cancerous conditions have become less frequent, as the journal prioritizes research that directly impacts cancer treatment and understanding.
  3. Single-Agent Drug Studies:
    The prevalence of studies evaluating the efficacy of single-agent drugs has waned, with a growing emphasis on combination therapies and multi-targeted approaches to overcome resistance and enhance treatment outcomes.

Similar Journals

Gastric Cancer

Leading the Charge in Gastric Cancer Discovery.
Publisher: SPRINGERISSN: 1436-3291Frequency: 4 issues/year

Gastric Cancer is a leading journal in the field of oncology, published by SPRINGER in Japan. With an ISSN of 1436-3291 and an E-ISSN of 1436-3305, this esteemed journal aims to disseminate high-quality research focused on all aspects of gastric cancer, including its pathophysiology, diagnosis, treatment, and prevention. As an indicator of its academic excellence, Gastric Cancer is ranked in the top quartile (Q1) for Cancer Research, Gastroenterology, Medicine (miscellaneous), and Oncology categories as of 2023. The journal holds impressive Scopus rankings, being positioned #9 in Gastroenterology and #34 in Oncology, demonstrating its critical role in shaping advancements within these disciplines. Although not an open-access publication, it provides various access options for institutions and individuals looking to elevate their understanding of gastric cancer. With a converged publication history from 2000 to 2024, it serves as a vital resource for researchers, professionals, and students dedicated to eradicating this formidable disease.

PATHOLOGY & ONCOLOGY RESEARCH

Exploring the Nexus of Disease and Treatment
Publisher: FRONTIERS MEDIA SAISSN: 1219-4956Frequency: 1 issue/year

PATHOLOGY & ONCOLOGY RESEARCH is a prominent international journal published by FRONTIERS MEDIA SA, dedicated to advancing the fields of pathology and oncology. Operating from the Netherlands, with a distinguished address in Switzerland, this journal plays a crucial role in disseminating significant research findings and insights from 1995 to 2024. With an ISSN of 1219-4956 and E-ISSN of 1532-2807, it is indexed in well-respected databases, facilitating access to a global audience of researchers and practitioners. Notably, the journal ranks in the Q3 category for Cancer Research (2023), while being recognized in the Q2 categories for both Medicine (Miscellaneous), Oncology, and Pathology and Forensic Medicine, reflecting its authoritative status in these vital disciplines. Scopus rankings further highlight its influence, with notable percentiles across various fields. Although it follows a subscription model, the journal remains committed to publishing high-quality, peer-reviewed research that bridges conceptual gaps and encourages further exploration in oncology and diagnostic pathology, making it an indispensable resource for academics and professionals engaged in these critical areas of medicine.

Oncologie

Exploring innovative solutions in oncology.
Publisher: WALTER DE GRUYTER GMBHISSN: 1292-3818Frequency: 6 issues/year

Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.

CANCER BIOLOGY & THERAPY

Pioneering discoveries in the battle against cancer.
Publisher: TAYLOR & FRANCIS INCISSN: 1538-4047Frequency: 12 issues/year

CANCER BIOLOGY & THERAPY is a premier open-access journal published by Taylor & Francis Inc, dedicated to advancing the field of cancer research and treatment. Since its inception in 2002, the journal has evolved to provide a platform for innovative research and groundbreaking findings, addressing critical aspects of cancer biology, pharmacology, and molecular medicine. With an impressive impact factor and recognition as a Q2 journal in vital categories such as Cancer Research, Oncology, and Pharmacology, it holds significant standing in Scopus rankings, reflecting its influence and commitment to disseminating high-quality research. Offering researchers, professionals, and students a wealth of knowledge, CANCER BIOLOGY & THERAPY stands at the forefront of the fight against cancer, presenting the latest developments and therapeutic strategies vital for improving patient outcomes. Accessible to all since 2022, this journal is a must-read for anyone involved in the multifaceted arena of cancer research and treatment.

Annual Review of Cancer Biology

Unraveling Innovations in Oncology
Publisher: ANNUAL REVIEWSISSN: 2472-3428Frequency: 1 issue/year

Annual Review of Cancer Biology is a pivotal journal published by Annual Reviews, specializing in the rapidly evolving field of cancer research. With an impact factor positioned in the distinguished Q1 quartile of Cancer Research, Cell Biology, and Oncology categories, this journal ensures that it showcases the highest quality of scholarly contributions. Indexed in Scopus, it ranks among the top in its fields, reflecting its strong influence and relevance, with remarkable percentiles indicating its esteemed position within the research community. Although not an open-access journal, it provides a comprehensive platform for advancing the frontiers of cancer biology through rigorously curated reviews, highlighting key developments, breakthroughs, and future directions that inform both academia and clinical applications. As a valuable resource for researchers, professionals, and students, the Annual Review of Cancer Biology serves as an essential guide for understanding and addressing the complexities of cancer biology today.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Pioneering Insights in Oncology and Genetics
Publisher: ELSEVIERISSN: 0304-419XFrequency: 4 issues/year

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, published by Elsevier, has established itself as a leading journal in the domains of cancer research, genetics, and oncology, holding a prestigious position in the Q1 quartile rankings in these fields as of 2023. With an ISSN of 0304-419X and an E-ISSN of 1879-2561, this journal aims to disseminate high-quality, impactful reviews that synthesize the latest advancements and findings in cancer biology, treatment modalities, and genomic studies. Its robust indexing and remarkable Scopus rankings—placing it in the 95th to 91st percentiles across various categories—underline its significance for researchers, clinicians, and students passionate about oncology. Operating from its Netherlands headquarters, BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER is dedicated to fostering a comprehensive understanding of the complex biological mechanisms underlying cancer, promoting innovative therapeutic strategies, and guiding future research directions.

INTERNATIONAL JOURNAL OF ONCOLOGY

Empowering breakthroughs in oncology and patient care.
Publisher: SPANDIDOS PUBL LTDISSN: 1019-6439Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.

CURRENT CANCER DRUG TARGETS

Unveiling novel therapeutic avenues in the fight against cancer.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1568-0096Frequency: 11 issues/year

CURRENT CANCER DRUG TARGETS is a prominent academic journal published by Bentham Science Publishers Ltd, focusing on the critical intersection of cancer research and innovative drug development. Since its inception in 2001, this journal has offered a platform for the dissemination of cutting-edge research aimed at advancing targeted cancer therapies, contributing significantly to the fields of Cancer Research, Drug Discovery, Oncology, and Pharmacology. With a respectable impact factor and consistent ranking in its respective categories, including Q2 in Drug Discovery and Pharmacology, it positions itself as an invaluable resource for researchers, clinicians, and students alike. CURRENT CANCER DRUG TARGETS is dedicated to enhancing our understanding of novel therapeutic targets and methods, thereby fostering a collaborative environment for knowledge exchange in the ever-evolving landscape of cancer treatment.

Breast Cancer-Targets and Therapy

Uniting researchers and practitioners for breast cancer solutions.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-1314Frequency: 1 issue/year

Breast Cancer-Targets and Therapy is a leading journal in the field of oncology, published by DOVE MEDICAL PRESS LTD in New Zealand. Established as an Open Access journal in 2009, it offers a platform for researchers and healthcare professionals to disseminate innovative findings and therapeutic strategies related to breast cancer. With an impressive ranking in the Q2 category of oncology journals as of 2023, and placed at Rank #203/404 in the Scopus database, this journal facilitates the exchange of high-quality research aimed at improving patient outcomes and advancing clinical practices. Covering a wide array of topics from basic research to clinical trials, Breast Cancer-Targets and Therapy plays a crucial role in bridging the gap between scientific discovery and practical application. Researchers, professionals, and students alike will find the journal a valuable resource for the latest advancements and best practices in breast cancer treatment.

ONCOLOGY RESEARCH

Elevating Knowledge in the Fight Against Cancer
Publisher: TECH SCIENCE PRESSISSN: 0965-0407Frequency: 6 issues/year

ONCOLOGY RESEARCH, published by TECH SCIENCE PRESS, is a vital academic journal dedicated to the rapidly evolving field of oncology. With its ISSN 0965-0407 and E-ISSN 1555-3906, the journal serves as a key resource for researchers, clinicians, and academicians committed to advancing cancer research and treatment strategies. Operating without an Open Access model, ONCOLOGY RESEARCH provides high-quality, peer-reviewed articles that cover diverse topics within cancer research, medicine, and oncology, with its 2023 Scopus ranking placing it in the Q3 quartile. The journal's commitment to facilitating rigorous scientific discourse is evident in its historical breadth, with a publishing history dating back to 1992. ONCOLOGY RESEARCH is not only significant for the academic community but also plays a critical role in fostering new insights and approaches in the fight against cancer, making it a must-read for those involved in this critical area of study.